SG151315A1 - Human glp-1 mimetibodies, compositions, methods and uses - Google Patents

Human glp-1 mimetibodies, compositions, methods and uses

Info

Publication number
SG151315A1
SG151315A1 SG200902141-1A SG2009021411A SG151315A1 SG 151315 A1 SG151315 A1 SG 151315A1 SG 2009021411 A SG2009021411 A SG 2009021411A SG 151315 A1 SG151315 A1 SG 151315A1
Authority
SG
Singapore
Prior art keywords
methods
compositions
mimetibodies
glp
human glp
Prior art date
Application number
SG200902141-1A
Other languages
English (en)
Inventor
Karyn Oaeneil
Kristen Picha
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of SG151315A1 publication Critical patent/SG151315A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200902141-1A 2004-03-31 2005-03-28 Human glp-1 mimetibodies, compositions, methods and uses SG151315A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55798304P 2004-03-31 2004-03-31
US61298104P 2004-09-24 2004-09-24

Publications (1)

Publication Number Publication Date
SG151315A1 true SG151315A1 (en) 2009-04-30

Family

ID=35125618

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902141-1A SG151315A1 (en) 2004-03-31 2005-03-28 Human glp-1 mimetibodies, compositions, methods and uses

Country Status (17)

Country Link
US (1) US20070135338A1 (ko)
EP (1) EP1750754A4 (ko)
JP (1) JP2008537873A (ko)
KR (1) KR20070004078A (ko)
AR (1) AR049014A1 (ko)
AU (1) AU2005231359A1 (ko)
BR (1) BRPI0509528A (ko)
CA (1) CA2563379A1 (ko)
CR (1) CR8706A (ko)
EA (2) EA011583B1 (ko)
IL (1) IL178432A0 (ko)
MX (1) MXPA06011425A (ko)
NO (1) NO20064953L (ko)
SG (1) SG151315A1 (ko)
TW (1) TW200602491A (ko)
WO (1) WO2005097175A2 (ko)
ZA (1) ZA200709266B (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042781A1 (en) * 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
ES2363023T3 (es) * 2004-10-25 2011-07-19 Centocor Ortho Biotech Inc. Mimeticuerpos de unión a receptor de melanocortina, composiciones, procedimientos y usos.
WO2007046834A2 (en) * 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
BRPI0520168A2 (pt) * 2005-03-28 2009-04-22 Centocor Inc mimeticorpos de glp-1 humanos, composiÇÕes, mÉtodos e usos
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113665A2 (en) * 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2658673A1 (en) * 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
CA2627444A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP2009526750A (ja) * 2005-12-22 2009-07-23 セントカー・インコーポレーテツド Ｇｌｐ−１アゴニスト、組成物、方法および使用
EP2007602A4 (en) * 2006-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
JP2010500868A (ja) * 2006-07-18 2010-01-14 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
WO2008028117A2 (en) * 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
UY30820A1 (es) * 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
EP2282770B1 (en) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
EP2303247A4 (en) * 2008-07-21 2012-08-01 Syneron Medical Ltd TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
SI2786762T1 (sl) * 2008-12-19 2019-07-31 Macrogenics, Inc. Kovalentna diatelesa in njihove uporabe
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US8948863B2 (en) * 2009-10-09 2015-02-03 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
BR112012010252A2 (pt) 2009-10-29 2016-12-06 Janssen Biotech Inc variantes de glicosilação de anticorpo
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
HUE045487T2 (hu) 2010-03-04 2019-12-30 Macrogenics Inc B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012259162C1 (en) 2011-05-21 2020-05-21 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AP2015008740A0 (en) 2013-03-14 2015-09-30 Macrogenics Inc Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
CA2907848A1 (en) 2013-04-03 2014-10-09 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2021195344A2 (en) * 2020-03-25 2021-09-30 The General Hospital Corporation Compositions and methods for diabetes treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) * 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US4767402A (en) * 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
EP0545913B1 (en) * 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5404871A (en) * 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
AU662919B2 (en) * 1991-07-02 1995-09-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1994006498A1 (en) 1992-09-23 1994-03-31 Fisons Plc Inhalation device
KR0177265B1 (ko) 1992-10-19 1999-04-01 미첼 알. 우드베리 건분말 흡입기
US5643252A (en) * 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JP3549533B2 (ja) 1993-01-19 2004-08-04 グラクソ、グループ、リミテッド 装置
JP3824633B2 (ja) * 1993-02-12 2006-09-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ 標的遺伝子の調節的転写および他の生物学的結果
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1996036883A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Immunoassay for glucagon like protein 1 (glp-1) in plasma
US5730723A (en) * 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
TR199801265T2 (xx) 1996-01-03 1998-10-21 Glaxo Group Limited ��e soluma cihaz�.
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6849719B2 (en) * 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
CA2364330A1 (en) * 1998-10-21 2000-04-27 Zymogenetics, Inc. Secreted protein zsig49
AU3224700A (en) * 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
SI1355942T1 (sl) * 2000-12-07 2009-02-28 Lilly Co Eli Glp-1 fuzijski proteini
WO2003083071A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
WO2004002424A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
AU2003280130B2 (en) * 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
EA200702093A1 (ru) 2009-06-30
ZA200709266B (en) 2009-05-27
NO20064953L (no) 2006-12-18
EP1750754A4 (en) 2010-09-22
EA011583B1 (ru) 2009-04-28
JP2008537873A (ja) 2008-10-02
WO2005097175A3 (en) 2009-11-19
CA2563379A1 (en) 2005-10-20
TW200602491A (en) 2006-01-16
EP1750754A2 (en) 2007-02-14
CR8706A (es) 2009-01-16
US20070135338A1 (en) 2007-06-14
WO2005097175A2 (en) 2005-10-20
AU2005231359A1 (en) 2005-10-20
IL178432A0 (en) 2007-02-11
BRPI0509528A (pt) 2007-08-07
KR20070004078A (ko) 2007-01-05
AR049014A1 (es) 2006-06-21
EA200601603A1 (ru) 2007-08-31
MXPA06011425A (es) 2007-03-12

Similar Documents

Publication Publication Date Title
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
LUC00121I1 (ko)
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
TW200626173A (en) IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2005028511A3 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
TW200716173A (en) Anti-IL-6 antibodies, compositions, methods and uses
WO2003086451A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
WO2006039638A3 (en) Treating renal cell carcinoma with an anti-tnf human antibody or fragment
MX2007011975A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos.
WO2003082206A3 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
WO2006110507A3 (en) Plant phytase genes and methods of use
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof